Kuna bin labaran Bluebird Bio? Idan ba haka ba, lokaci ya yi da za ku sani kuma kunna sanarwarku don duk sabbin abubuwan sabuntawa game da wannan kamfani. Domin ana nuna ta zuwa wani sabon matsayi a kowane lokaci.
Ana sa ran cewa hannayen jari na wannan kamfani na iya yin tashin gwauron zabi kamar yadda kwamitin ba da shawara na Hukumar Abinci da Magunguna (FDA) ya ba da shawarar gwaje-gwaje biyu na gwajin gwajin kwayoyin halittar wannan kamfanin.
Don haka mai yiwuwa ka ga hannun jarin kamfani yana hawa da sama kawai. Don bayanin ku, alamar 'BLUE' da kuke iya gani akan allo na wannan kamfani ne. Don haka duk da yanayin kasuwa gabaɗaya, masu hannun jarin wannan kamfani suna samun ɗan jinkiri da ake buƙata.
Muhimman Labarai na Bluebird Bio
Wannan kamfani ne na Cambridge, Massachusetts wanda ke da tushen ilimin kimiyyar halittu wanda ke mai da hankali kan haɓaka hanyoyin kwantar da hankali ga cututtukan ƙwayoyin cuta masu tsanani da ciwon daji. A baya can, maganin sa kawai da aka amince da shi daga Tarayyar Turai (EU) shine Betigeglogene autotemcel wanda aka fi sani da (Zynteglo).
Don tunatar da ku, wannan shi ne magani na biyu mafi tsada a duniya wanda aka kashe dala miliyan 1.8. Da yawan yuwuwar kamfanin ya ga hannun jarinsa ya hauhawa amma sun yi ta raguwa har zuwa yanzu. Tare da amincewar hanyoyin kwantar da hankali guda biyu, ana sa ran dawo da amincewar da aka rasa a nan gaba daga masu zuba jari.
Sauran ayyukan bututun kamfanin sun hada da LentiGlobin genetherapy don cutar Sickle cell da Cerebral Adrenoleukodystrophy. Hakanan IT yana aiki don magance cutar sankarar ƙwayar cuta ta Myeloid, kansar Merkel-cell, MAGEA4 ƙwanƙwaran ciwace-ciwacen daji, da Diffous babban lymphoma B-cell.
Fara tafiyar ta a matsayin Genetix Pharmaceuticals a cikin 1992 na ƙwararrun membobin MIT Irving London da Philippe Leboulch, wannan ƙungiyar fasahar kere kere ta ga hannun jarin ta ya haura zuwa $178.29 a cikin 2018 kuma bayan haka, sun kasance kan faɗuwa gabaɗaya.
Amma tare da wannan labari, hannun jarin ya karu da kusan kashi 28.7% zuwa 4.80 a ranar Litinin 14 ga Yuni 2022. Hannun jarin suna kan hanya don karuwar kashi mafi girma a cikin shekaru takwas da suka gabata, kamar yadda bayanai daga Dow Jones Market Data. Yana da mahimmanci a san cewa hannun jarin ya ragu sama da 46% a wannan shekara.
Ana sa ran tsalle a cikin ƙima daga shawarar hanyoyin ilimin halittar halittu ta Hukumar Abinci da Magunguna. A ranar 9 ga Yuni Kwamitin Shawarwari na Salon Jiki, Tissue, da Gene Therapies na FDA sun ba da shawarar elivadogene autotmcel ko Eli-CEL genetherapy.
Ana amfani da wannan maganin a cikin maganin cutar da ke da alaƙa da X chromosome, farkon adrenoleukodystrophy cerebral mai aiki. A ranar Juma'a, wannan ƙungiyar ta gwamnati ta ba da shawarar Betibeglogene autotemcel ko beti-cel, wannan magani ne na lokaci ɗaya da aka tsara don kula da marasa lafiyar beta-thalassemia.
Bayan maganin, ba za a buƙaci ƙarin ƙarin kwayar cutar jan jini ga majinyata da cutar ta shafa, waɗanda in ba haka ba suna buƙatar ta akai-akai. Ana sa ran FDA za ta yanke shawarar hukuma don beti-cel a ranar 19 ga Agusta kuma ranar Eli-CEL ita ce 16 ga Satumbar wannan shekara.
Kammalawa
Da wannan babban labari, jama'a sun fara sha'awar hannun jarin kamfanin kuma wannan shine dalilin da ya sa labarai na Bluebird Bio ke zagayawa a wuraren hada-hadar kudi a kasuwannin. Duk inda farashin ya tafi, ana sa ran bluebird zai amfana sosai daga waɗannan shawarwarin.